SBIO - CymaBay: Long-Term Potential Based On Prior PBC Trial Results
- Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023.
- PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival.
- The global Primary Biliary Cholangitis treatment market size is estimated to be worth $812.6 million in 2022 and could reach $2.5 billion by 2028.
- Two other indications in which Seladelpar can be used for are non-alcoholic steatohepatitis and primary sclerosing cholangitis.
For further details see:
CymaBay: Long-Term Potential Based On Prior PBC Trial Results